Literature DB >> 2787610

Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis.

J Müller-Quernheim1, M Krönke, J Strausz, M Schykowski, R Ferlinz.   

Abstract

Current concepts of the immunopathogenesis of sarcoidosis favor a central role of activated, interleukin-2 (IL-2) producing helper T-cells at sites of inflammation. Normally, activated T-cells release IL-2 and express IL-2 receptors (IL-2R). IL-2R+ cells, however, are not uniformly found in patients with clinically active disease. To determine whether the lack of IL-2R+ cells is caused by a dysregulation of the IL-2R gene or by the mode of T-cell activation in pulmonary sarcoidosis, we quantified IL-2 and IL-2R m-RNA transcripts, IL-2 release, and IL-2R surface protein in peripheral blood lymphocytes of patients with sarcoidosis and normal control subjects before and after in vitro stimulation as a function of time. Additionally, we determined the percentage of IL-2R+ bronchoalveolar lavage (BAL) and peripheral blood lymphocytes in our study population and evaluated the in vivo transcriptional activity of the IL-2R gene. In peripheral blood lymphocytes, maximal IL-2R mRNA accumulation is found between 6 and 24 h, and maximal accumulation of IL-2 mRNA is found between 24 and 48 h. No differences emerged between normal subjects and patients with sarcoidosis. In six of 19 patients, we observed elevated numbers of IL-2R+ BAL lymphocytes and found IL-2R mRNA in those cells. These results are in accordance with the concept of a compartmentalized T-cell activation in sarcoidosis, resulting in IL-2 and IL-2R positive BAL cells and quiescent peripheral blood lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787610     DOI: 10.1164/ajrccm/140.1.82

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells.

Authors:  A Prasse; C G Georges; H Biller; H Hamm; H Matthys; W Luttmann; J C Virchow
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.

Authors:  I Bäumer; G Zissel; M Schlaak; J Müller-Quernheim
Journal:  Lung       Date:  1997       Impact factor: 2.584

3.  Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation.

Authors:  T Koura; Y Gon; S Hashimoto; A Azuma; S Kudoh; Y Fukuda; I Sugawara; J Yodoi; T Horie
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

4.  Correlation of plasma monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1alpha (MIP-1alpha) levels with disease activity and clinical course of sarcoidosis.

Authors:  S Hashimoto; T Nakayama; Y Gon; N Hata; T Koura; S Maruoka; K Matsumoto; S Hayashi; Y Abe; T Horie
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

5.  Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis.

Authors:  J Homolka; J Lorenz; H D Zuchold; J Müller-Quernheim
Journal:  Clin Investig       Date:  1992-10

6.  Lung lymphocytes proliferate minimally in the murine pulmonary immune response to intratracheal sheep erythrocytes.

Authors:  G D Seitzman; J Sonstein; S Kim; W Choy; J L Curtis
Journal:  Am J Respir Cell Mol Biol       Date:  1998-06       Impact factor: 6.914

7.  Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis.

Authors:  J Müller-Quernheim; S Pfeifer; K Kienast; G Zissel
Journal:  Lung       Date:  1996       Impact factor: 2.584

8.  Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis.

Authors:  J Müller-Quernheim
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

9.  Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis.

Authors:  S Kullberg; N V Rivera; M Abo Al Hayja; J Grunewald; A Eklund
Journal:  Clin Exp Immunol       Date:  2020-04-22       Impact factor: 4.330

Review 10.  Bronchoalveolar lavage.

Authors:  W R Martin; P A Padrid; C E Cross
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.